Product Details
| Product Name:
ML335 |
CAS No.:
825658-06-8 |
| Purity:
99.73% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | ML335 |
| Description | ML335 is a selective activator of TREK-1 and TREK-2. |
| Cell Research | Mouse K2P2.1, human K2P4.1, and mutants are expressed from a previously described pIRES2-EGFP vector in HEK293T cells (ATTC). 70% confluent cells are transfected (in 35-mm diameter wells) with LipofectAMINE 2000 for 6?h, and plated onto coverslips coated with Matrigel. Effects of ML335, ML402 and arachidonic acid on K2P2.1 current at 0?mV are measured by whole-cell patch-clamp experiments 24?h after transfection. Acquisition and analysis are performed using pCLAMP9 and an Axopatch 200B amplifier. Pipette resistance ranges from 1 to 1.5?MΩ. Pipette solution contains the following: 145?mM KCl, 3?mM MgCl2, 5?mM EGTA and 20?mM HEPES (pH 7.2 with KOH). Bath solution contains the following: 145?mM NaCl, 5?mM KCl, 1?mM CaCl2, 3?mM MgCl2 and 20?mM HEPES (pH 7.4 with NaOH). K2P2.1 currents are elicited by a 1?s ramp from -100 to +50?mV from a -80?mV holding potential. After stabilization of the basal current, ML335 and ML402 are perfused at 200?mL per hour until potentiation is stably reached[1]. |
| In vitro | Xenopus oocyte two-electrode voltage-clamp measurements indicate that ML335 and ML402 activate K2P2.1 and K2P10.1, but not K2P4.1 (14.3±2.7 μM for K2P2.1-ML335; 13.7±7.0 μM for K2P2.1-ML402; 5.2±0.5 μM for K2P10.1-ML335; and 5.9±1.6 μM for K2P10.1-ML402). Swapping the Lys271 equivalent between K2P2.1 and K2P4.1 results in a reversed phenotype for ML335 and ML402 activation. ML335 and ML402 also activate K2P2.1 in HEK293 cells in a manner similar to their effects in Xenopus oocytes (5.2±0.8 μM and 5.9±1.6 μM for ML335 and ML402, respectively [n≥3]). |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 45 mg/mL (120.56 mM)
|
| Keywords | Potassium Channel | ML-335 | ML 335 | ML335 | KcsA | Inhibitor | inhibit |
| Inhibitors Related | Minoxidil sulfate | Quinine | (±)-Naringenin | Tolbutamide | Tetraethylammonium bromide | Halothane | Butamben | Tetraethylammonium chloride | Cloperastine hydrochloride | 2,2,2-Trichloroethanol | Chlorzoxazone | Indapamide |
| Related Compound Libraries | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Neuroprotective Compound Library | NO PAINS Compound Library | Potassium Channel Targeted Library | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:2684216-48-4
$239.00 / 1mg
-
CAS:569-77-7
$48.00 / 5mg
-
CAS:2210247-59-7
$98.00 / 1mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States